Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Kojonazarov, M. Lang, N. Weissmann, F. Grimminger, J. P. Stasch, W. Seeger, H. A. Ghofrani, R. Schermuly (Giessen, Wuppertal, Bad Nauheim, Germany). Effects of riociguat in severe experimental pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 411

Member's Comments

No comment yet.

Related content which might interest you: Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Effects of fasudil in patients with high-altitude pulmonary hypertension Source: Eur Respir J 2012; 39: 496-498 Year: 2012 The progression towards pulmonary arterial hypertension is attenuated by bosentan in scleroderma patients Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Therapeutic update of severe pulmonary hypertension in COPD Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD Year: 2010 The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Effects of sildenafil on secondary pulmonary hypertension in highlanders with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 73s Year: 2007 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Effect of simvastatin on pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 287s Year: 2007 Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Comparative effects of amlodipine and sildenafil on the NT-proBNP levels of patients with COPD-induced pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Inhaled iloprost reverses chronic experimental pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 353s Year: 2005 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017